# Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

> **NCT00138840** · PHASE2 · COMPLETED · sponsor: **Synta Pharmaceuticals Corp.** · enrollment: 282 (—)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** STA-5326 mesylate

## Key facts

- **NCT ID:** NCT00138840
- **Lead sponsor:** Synta Pharmaceuticals Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 282 (—)
- **Last updated:** 2008-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138840, "Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00138840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*